Carter Lawrence P, Wu Huifang, Chen Weibin, Matthews Marilyn M, Mehta Ashok K, Hernandez R Jason, Thomson Jennifer A, Ticku Maharaj K, Coop Andrew, Koek Wouter, France Charles P
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, 78229-3900, USA.
J Pharmacol Exp Ther. 2005 Jun;313(3):1314-23. doi: 10.1124/jpet.104.077578. Epub 2005 Mar 15.
gamma-Hydroxybutyrate (GHB), a therapeutic for narcolepsy and a drug of abuse, has several mechanisms of action that involve GHB and GABA(B) receptors, metabolism to GABA, and modulation of dopaminergic signaling. The aim of these studies was to examine the role of GHB and GABA(B) receptors in the behavioral effects of GHB. Three approaches were used to synthesize GHB analogs that bind selectively to GHB receptors and are not metabolized to GABA-active compounds. Radioligand binding assays identified UMB86 (4-hydroxy-4-napthylbutanoic acid, sodium salt), UMB72 [4-(3-phenylpropyloxy)butyric acid, sodium salt], UMB73 (4-benzyloxybutyric acid, sodium salt), 2-hydroxyphenylacetic acid, 3-hydroxyphenylacetic acid (3-HPA), and 4-hydroxy-4-phenylbutyric acid as compounds that displace [(3)H]NCS-382 [5-[(3)H]-(2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7] annulen-6-ylidene) ethanoic acid] from GHB receptors at concentrations that do not markedly affect [(3)H]GABA binding to GABA(B) receptors. In rats and pigeons, GHB discriminative stimulus effects were not mimicked or attenuated by UMB86, UMB72, or 3-HPA up to doses that decreased responding. In mice, GHB, GHB precursors (gamma-butyrolactone and 1,4-butanediol) and GABA(B) receptor agonists [SKF97541 [3-aminopropyl(methyl)phosphinic acid hydrochloride] and baclofen] dose-dependently produced hypolocomotion, catalepsy, ataxia, and loss of righting. The GABA(B) receptor antagonist CGP35348 (3-aminopropyl(diethoxymethyl)phosphinic acid) attenuated catalepsy and ataxia that was observed after GHB and GABA(B) receptor agonists SKF97541 and baclofen. UMB86, UMB72, UMB73, and 3-HPA, like GHB, produced hypolocomotion, ataxia, and loss of righting; however, catalepsy was never observed with these compounds, which is consistent with the cataleptic effects of GHB being mediated by GABA(B) receptors. Ataxia that was observed with UMB86, UMB72, UMB73, and 3-HPA was not antagonized by CGP35348, suggesting that ataxia induced by these analogs is not mediated by GABA(B) receptors and might involve GHB receptors.
γ-羟基丁酸(GHB)是一种用于治疗发作性睡病的药物,也是一种滥用药物,它有多种作用机制,涉及GHB和GABA(B)受体、代谢为GABA以及对多巴胺能信号的调节。这些研究的目的是研究GHB和GABA(B)受体在GHB行为效应中的作用。采用了三种方法来合成选择性结合GHB受体且不会代谢为具有GABA活性化合物的GHB类似物。放射性配体结合试验确定UMB86(4-羟基-4-萘基丁酸,钠盐)、UMB72 [4-(3-苯丙氧基)丁酸,钠盐]、UMB73(4-苄氧基丁酸,钠盐)、2-羟基苯乙酸、3-羟基苯乙酸(3-HPA)和4-羟基-4-苯基丁酸为能在不显著影响[(3)H]GABA与GABA(B)受体结合的浓度下,从GHB受体上取代[(3)H]NCS-382 [5-[(3)H]-(2E)-(5-羟基-5,7,8,9-四氢-6H-苯并[a][7]环壬烯-6-亚基)乙酸]的化合物。在大鼠和鸽子中,高达降低反应的剂量时,UMB86、UMB72或3-HPA都不会模拟或减弱GHB的辨别刺激效应。在小鼠中,GHB、GHB前体(γ-丁内酯和1,4-丁二醇)以及GABA(B)受体激动剂[SKF97541 [3-氨基丙基(甲基)次膦酸盐酸盐]和巴氯芬]剂量依赖性地产生运动减少、僵住、共济失调和翻正反射丧失。GABA(B)受体拮抗剂CGP35348(3-氨基丙基(二乙氧基甲基)次膦酸)减弱了GHB以及GABA(B)受体激动剂SKF97541和巴氯芬后观察到的僵住和共济失调。UMB86、UMB72、UMB73和3-HPA与GHB一样,产生运动减少、共济失调和翻正反射丧失;然而,这些化合物从未观察到僵住现象,这与GHB的僵住效应由GABA(B)受体介导一致。CGP35348未拮抗UMB86、UMB72、UMB